ISTH 2020 Congress
Platelet Disorders and von Willebrand Disease » Platelet Antagonists and Novel Therapeutics
Theme Navigation
- ISTH 2020 Congress
- Platelet Disorders and von Willebrand Disease
- Platelet Antagonists and Novel Therapeutics
- Platelet Disorders and von Willebrand Disease
-
Abstract Number: PB1469
Antithrombotic Therapy by Charged Nanoparticles
-
Abstract Number: PB1455
High-Dose Dexamethasone Effectively Replaces Traditional Full-Dose Prednisone as the First-Line Treatment of Children Immune Thrombocytopenia: A Prospective Randomized Single-Center Study
-
Abstract Number: PB1467
Idelalisib Selectively Inhibits GPVI-mediated Platelet Activation and Shows Anti-atherothrombotic Activity
-
Abstract Number: PB1459
Identification of the Sequence Specificity in C-Src SH3 Required for Binding to Integrin Β3 as a Novel Anti-Thrombotic Target without Compromising Primary Hemostasis
-
Abstract Number: PB1460
Inhibition of Platelet Adhesion, Thrombus Formation and Fibrin Formation by a Potent αIIbβ3 Integrin Inhibitor
-
Abstract Number: PB1466
Method of Anticoagulation Influences Potency of Reversible P2Y12 Receptor Antagonists
-
Abstract Number: PB/LB05
Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia
-
Abstract Number: PB1468
Role of Multidrug Resistance Protein 4 on Both Platelet Nitric Oxide Resistance and ADP Induced Platelet Aggregation
-
Abstract Number: PB1465
Selatogrel, a Potent P2Y12 Receptor Antagonist, Dissolves Pre-Formed Platelet-thrombi in vivo